Morning Overview on MSN

A new non-opioid painkiller is the first fresh pain-drug class in decades

Adults recovering from surgery now have access to a pain drug that works through an entirely different biological mechanism ...

Johnson & Johnson (JNJ) Q2 2026 Earnings Call Transcript

Q2 2026 Earnings Call July 15, 2026 8:30 AM EDTCompany ParticipantsRyan KoorsJoaquin Duato - CEO & ChairmanJoseph Wolk ...

Johnson & Johnson signals 2026 sales midpoint of $100.6B and adjusted operational EPS of $11.50-$11.65, driven by new launches

Johnson & Johnson Q2 2026 earnings call: raised guidance, $25.3B sales, ICOTYDE/INLEXZO momentum, MedTech Abiomed risks & catalysts—read now.